Welcome to the 24th edition of the Special Situations Digest.

📥 Download Excel File📕 Download PDF🗂 Download JSON

Activist Campaigns

Compass Diversified CODI (US) · $10.33 · MCAP $777M · EV $3.4B
Fwd P/E: 36.2x · Fwd EV/EBITDA: 12.0x · Fwd EV/GP: 4.1x · LTM EV/Sales: 1.8x · LTM EV/GP: 4.1x
Compass Diversified is a private equity firm specializing in add on acquisitions, buyouts, industry consolidation, recapitalization, late stage, and middle market investments. The firm prefers to invest in companies based in North America.
Updated 2026-07-18
ADW Capital Management holds about 19.3% of Compass Diversified's stock. ADW sent an open letter urging the board to begin an immediate strategic review and consider orderly liquidation. ADW estimates potential value creation of $50 to $60 per share by internalizing the external manager. The letter highlights concerns over board independence and conflicts of interest, and threatens a proxy contest if the board does not engage.
Exicure, Inc. XCUR (US) · $1.68 · MCAP $11M · EV $8M · Healthcare / Biotechnology
Exicure, Inc. does not have significant operations. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.
Updated 2026-07-16
Exicure HiTron Inc. consolidated its stake in Exicure, Inc. (XCUR) to 34.87% by reacquiring 623,277 shares. The reporting person recovered these shares from five prior transferees through share transfer amendment agreements dated June 23 and June 26, 2026. Following these transfers, the reporting person beneficially owns 2,222,224 shares. The reporting person is pursuing remedies under pledge arrangements to recover an additional 487,834 shares from two non-participating transferees, which could further increase the control block.
Shattuck Labs, Inc. STTK (US) · $7.53 · MCAP $719M · EV $632M · Healthcare / Biotechnology
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody.
Announced 2026-07-17
Redmile Group, LLC, Jeremy C. Green and Redmile Biopharma Investments II, L.P. reported beneficial ownership of 10,019,421 Shattuck Labs, Inc. (STTK) common shares, including warrant shares, or 9.9% as of July 17, 2026, compared with 9,819,084 shares and the same 9.9% in Amendment No. 5. Since the prior filing, Redmile reported selling an aggregate 1,948,851 common shares from July 10 through July 17 and purchasing 143,808 shares on July 17 for approximately $1 million at a weighted-average price of $7.46. The current beneficial-ownership total includes 4,786,345 shares issuable under pre-funded warrants subject to a 9.99% ownership limitation. The filing is Amendment No. 6 to Schedule 13D.
TransCode Therapeutics, Inc. RNAZ (US) · $11.06 · MCAP $9.4M · EV $3.1M · Healthcare / Biotechnology
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company is also developing oncolytic virus therapy.
Announced 2026-07-17
DEFJ, LLC, a subsidiary of CK Life Sciences, is increasing its stake in TransCode Therapeutics, Inc. (RNAZ) to approximately 9.99% via a preferred stock conversion. According to a Schedule 13D/A filed July 17, 2026, DEFJ provided an irrevocable notice to convert 21.6755 shares of Series B Preferred into 216,755 shares of Common Stock. This conversion is contingent upon stockholder approval of Proposals 1 and 2 at the 2026 annual meeting. DEFJ currently holds 83,285 shares, or 8.8% of the 950,302 shares outstanding as of May 12, 2026. The conversion links the stake increase to the upcoming proxy vote and brings DEFJ just below the 10% threshold that often triggers additional disclosure or governance scrutiny.
TransAct Technologies Inc. TACT (US) · $5.23 · MCAP $54M · EV $41M
Fwd EV/EBITDA: 46.3x · Fwd EV/GP: 1.6x · LTM EV/Sales: 0.8x · LTM EV/GP: 1.5x
TransAct Technologies Incorporated designs, develops, and markets transaction-based and specialty printers and terminals in the United States and internationally. The company also provides consumable products, including POS receipt paper, ribbons, and other printing supplies.
Announced 2026-07-17
Poplar Point Capital Management LLC, Poplar Point Capital Partners LP, Poplar Point Capital GP LLC and Jad Fakhry reported shared beneficial ownership of 1,563,752 shares, or 15.22%, of TransAct Technologies Inc. (TACT) in a Schedule 13D filed July 17, 2026. The group believes the shares are undervalued and has discussed, and intends to continue discussing, strategic alternatives for the casino and gaming ticket-printer business, financial-reporting segmentation, capital allocation, governance and board composition with management and the board.
Air T, Inc. AIRT (US) · $26.40 · MCAP $73M · EV $287M
Fwd EV/GP: 3.8x · LTM EV/Sales: 0.7x · LTM EV/GP: 3.3x
Air T, Inc. provides overnight air cargo; ground support equipment; commercial aircraft, engines, and parts; digital solutions; and regional airline services in the United States and internationally. The company's Overnight Air Cargo segment offers air express delivery services.
Updated 2026-07-15
Air T, Inc. (AIRT) is the subject of an ownership filing. Nicholas J. Swenson and affiliated entities disclosed a 48.3% stake in Air T, Inc. (AIRT) with an expressed intent to influence company policies and assert shareholder rights. The group holds 1,303,339 shares, having deployed approximately $11,600,977 of capital to build the position. According to Amendment No. 28 to the Schedule 13D filed July 15, 2026, the group reports no purchases or sales in the past sixty days.
Macnica Holdings, Inc. 3132.T (JP) · ¥3,201.00 · MCAP $3.5B · EV $3.7B
Fwd P/E: 16.4x · Fwd EV/EBITDA: 10.4x
Macnica Holdings, Inc. imports, sells, and exports electronic components in Japan.
Announced 2026-07-15
Dalton Investments increased its stake in Macnica Holdings, Inc. (3132.T) to 9.18% from 8.18%, according to Change Report No. 4 filed on July 15, 2026; the reporting-obligation date was July 8, 2026. Dalton reported holding 16,444,605 shares. The filing states that Dalton views the shares as undervalued, intends to hold them long term, and may seek constructive dialogue with the company, its officers and directors, and other shareholders regarding governance, board composition, management, business, financial condition, and strategy.
Tosei Corporation 8923.T (JP) · ¥1,783.00 · MCAP $1.1B · EV $1.9B
Fwd P/E: 10.1x · Fwd EV/EBITDA: 10.4x · Fwd EV/GP: 6.7x · LTM EV/Sales: 2.6x · LTM EV/GP: 6.8x
Tosei Corporation operates in the revitalization, development, rental, fund and consulting, property management, and hotel businesses in Japan. The company also provides asset management services for real estate funds.
Announced 2026-07-13
Dalton Investments increased its stake in Tosei Corporation (8923.T) to 6.07% from 5.00%, according to a change report filed on July 13, 2026; the reporting-obligation date was July 6, 2026. Dalton states that it views Tosei's shares as undervalued, intends to hold them long term, and may seek constructive dialogue on governance, board composition, management, business, financial condition, and strategy.
Intage Holdings Inc. 4326.T (JP) · ¥1,889.00 · MCAP $444M · EV $382M
Fwd EV/GP: 2.1x
INTAGE HOLDINGS Inc. operates as a marketing research company in Japan and internationally. The Business Intelligence segment develops data analysis systems and provides solutions for pharmaceutical, health information, manufacturing, travel, publishing, consumer goods manufacturer, services, advertising agency, wholesale.
Announced 2026-07-17
Nippon Active Value Fund took a 5.0% stake in Intage Holdings (4326.T). The fund disclosed the position through an initial 5%+ filing. This is a local large-shareholding filing.
Sankei Real Estate Investment Corporation 2972.T (JP) · ¥109,800.00 · MCAP $316M · EV $497M · Real Estate / REIT - Office
In October 2023, SANKEI REAL ESTATE converted from an office-building-oriented REIT to a comprehensive REIT due to partial amendments in its management guidelines of the Asset Management Company.
Announced 2026-07-14
City Index Eleventh and its joint holders increased their aggregate stake in Sankei Real Estate Investment Corporation (2972.T) from 28.51% to 29.56%, representing 138,094 units. The filing submitted July 14, 2026, was Change Report No. 12, with a July 7 reporting-obligation date; it was not an initial 5% filing.